ITGR

ANALYST NOTE: INTEGER HOLDINGS CORPORATION (ITGR) Date: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, Integer Holdings Corporation presents a confirmed coil setup. The structure has fired, indicating active readiness. The conservative entry level for this confirmed breakout is $100.38. The current price is $100.38, resulting in an extension of +0.0% from the conservative entry. The ATR at the time of the breakout was 2.7%, categorized as productive, and the current ATR remains at 2.7%, also productive. This volatility profile suggests a structural quality suitable for position sizing without the elevated risk associated with extreme volatility buckets. The setup is actionable; the base has formed and the breakout signal has been triggered.

(2) The Thesis Layer The primary secular thesis driving this setup is Biotech & GLP-1 → Platforms, Tools & CRO/CDMO, where Integer Holdings holds a direct beneficiary status with moderate confidence. As a leading global Contract Development and Manufacturing Organization (CDMO), ITGR sits at the critical infrastructure layer of the medical device value chain. While the company does not develop the GLP-1 drugs themselves, it provides the essential manufacturing, engineering, and device integration capabilities required for the broader cardio, vascular, and neuromodulation ecosystems that often accompany or support these therapeutic advancements. The company's exposure is direct to the "Platforms and Tools" tier, serving as the manufacturing backbone for major OEMs. There are no additional secular themes listed in the current membership, focusing the conviction entirely on the CDMO/medical device infrastructure narrative.

(3) The Business Integer Holdings Corporation operates as a global leader in outsourced medical device manufacturing, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. The company functions as a strategic partner to large, multinational Original Equipment Manufacturers (OEMs), including Abbott Laboratories, Boston Scientific, and Medtronic, which collectively accounted for 49% of total sales in 2025.

As of the Q1 2026 earnings transcript (source date 2026-04-30), the company reported first-quarter sales of $440 million, representing a 0.5% increase on a reported basis and a 1.3% increase on an organic basis. The business is segmented into three primary product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation (CRM&N), and Other Markets. The CRM&N segment specifically grew 5% year-over-year in Q1 2026, driven by Cardiac Rhythm Management growth, though this was partially offset by lower sales from a Neuromodulation customer.

Management has provided specific guidance regarding headwinds and growth expectations. For the full year 2026, management expects reported sales to decline by 1% to 3% compared to the prior year, with organic sales expected to be flat to down 1%. This outlook is primarily impacted by lower sales related to three new products due to lower-than-anticipated market adoption, creating a 3% to 4% headwind. Excluding these three products, management expects organic sales to grow approximately 3% to 4%, a slight reduction from their prior outlook of 4% to 6%. However, management anticipates a return to market growth in the fourth quarter of 2026, normalized for fiscal calendar production days.

Financially, the company maintains a Total Net Leverage Ratio of approximately 3.0:1.0 as of April 3, 2026. Management stated that projected cash flows, available cash, and borrowings under the Revolving Credit Facility are sufficient to meet working capital, debt service, and capital expenditure requirements for the next twelve months. The firm also maintains a firm backlog of approximately $675 million as of December 31, 2025, with the majority of these orders expected to be shipped within one year.

(4) The Archetype and Conviction Integer Holdings fits the Growth Leader archetype, though with a near-term inflection point. The company is executing a "tuck-in" acquisition strategy to add capabilities and scale, while simultaneously managing a strategic portfolio transition. The "Growth Leader" classification is supported by the company's position as a top-tier CDMO in high-growth therapeutic areas (electrophysiology, structural heart, neurovascular) and its ability to deliver consistent, albeit modest, organic growth in its core segments.

Valuation context is provided by the financial spine, which lists a forward consensus EPS of $6.08 for FY1 and $6.81 for FY2. The ATR of 2.7% is in the "productive" range, indicating healthy volatility that supports a breakout without the instability of extreme volatility. The conviction is built on the combination of a confirmed structural breakout, a strong backlog ($675M), and a clear path to returning to organic growth in Q4 2026, despite the current drag from three specific new products. The strategic review announced in April 2026, considering a sale, merger, or strategic combination, adds a layer of potential value creation that management is actively exploring.

(5) Invalidating Factors, Strengthening Factors, and Gaps

• Strengthening Factors: A return to the previously guided 4-6% organic growth rate in Q2 2026 would significantly strengthen the case, indicating the "risk adjustments" were temporary. Successful execution of the strategic review (e.g., a premium acquisition offer) would be a major catalyst. Continued growth in the CRM&N segment (currently +5%) would validate the core business strength.
• Invalidating Factors: A further widening of the headwind from the three new products beyond the current 3-4% estimate, or a failure to return to market growth in Q4 2026 as guided, would weaken the structural thesis. A significant deterioration in the leverage ratio or a breach of covenants would be a critical failure signal.
• Gaps in Evidence: The specific financial impact of the "strategic review" is currently unknown; there is no evidence yet on whether a deal will materialize or what the terms might be. The specific identity of the "Neuromodulation customer" causing the offset in Q1 is not disclosed. Additionally, while the backlog is strong, the specific mix of high-margin vs. low-margin products within the $675M backlog is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed coil breakout at $100.38 with productive ATR; $675M firm backlog with >1 year visibility; Management guidance for return to organic growth in Q4 2026. Key risks: 3-4% headwind from three new products persisting longer than expected; Strategic review outcome remains uncertain; Customer concentration risk (top 3 customers = 49% of sales). Rating boundary: This is rated Buy rather than Strong Buy because the near-term sales outlook (flat to down 1% organic) and the specific headwinds from new products introduce a period of uncertainty that prevents a top-tier conviction, despite the strong structural setup. It is rated Buy rather than Speculative because the confirmed coil, strong backlog, and clear path to Q4 growth provide a higher probability of success than a speculative setup. Sizing hint: Position size should reflect the productive ATR and the confirmed breakout, but be mindful of the near-term sales headwinds. Expected path: The company navigates the Q2 and Q3 headwinds, stabilizes the three new product lines, and executes the return to market growth in Q4, potentially leading to a re-rating as the strategic review concludes. Expected horizon: 12 to 18 months for the full thesis to play out, aligning with the Q4 2026 growth return and the strategic review timeline. Failure mode to watch: A failure to return to market growth in Q4 2026 as guided, or a significant widening of the headwind from the three new products.